“Pluripotency redux--advances in stem-cell research”.The New England Journal of Medicine357(15): 1469–72.(October 2007).doi:10.1056/NEJMp078126.PMID17928593.
“Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies”.Gynecologic Oncology130(3): 554–9.(September 2013).doi:10.1016/j.ygyno.2013.06.019.PMID23791828.
“Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose”.Acta Neuropathologica86(5): 456–65.(1993).doi:10.1007/bf00228580.PMID8310796.
Takahaski,Kazutoshi;Yamanaka,Shinya(17 Feb 2016).“A decade of transcription factor-mediated reprogramming to pluripotency”.Nature Reviews. Molecular Cell Biology17(3): 183–193.doi:10.1038/nrm.2016.8.PMID26883003.
“A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer”.The Journal of Biological Chemistry277(23): 20965–73.(June 2002).doi:10.1074/jbc.M112231200.PMID11916966.
“Inhibition of human telomerase reverse transcriptase gene expression by BRCA1 in human ovarian cancer cells”.Biochemical and Biophysical Research Communications303(1): 130–6.(March 2003).doi:10.1016/s0006-291x(03)00318-8.PMID12646176.
“BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells”.Oncogene17(15): 1939–48.(October 1998).doi:10.1038/sj.onc.1202403.PMID9788437.
“Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation”.The Journal of Biological Chemistry279(38): 40209–19.(September 2004).doi:10.1074/jbc.M404056200.PMID15210690.
“CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells”.The Journal of Biological Chemistry280(20): 20086–93.(May 2005).doi:10.1074/jbc.M410036200.PMID15769738.
“Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase”.The Journal of Biological Chemistry274(46): 32580–7.(November 1999).doi:10.1074/jbc.274.46.32580.PMID10551811.
“The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins”.Cell94(3): 363–74.(August 1998).doi:10.1016/s0092-8674(00)81479-8.PMID9708738.
“c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function”.Nature Genetics22(1): 102–5.(May 1999).doi:10.1038/8811.PMID10319872.
“Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX”.Oncogene22(6): 819–25.(February 2003).doi:10.1038/sj.onc.1206252.PMID12584560.
“Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors”.The Journal of Biological Chemistry274(51): 36344–50.(December 1999).doi:10.1074/jbc.274.51.36344.PMID10593926.
“Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc”.Oncogene16(9): 1149–59.(March 1998).doi:10.1038/sj.onc.1201634.PMID9528857.
“X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors”.Cell112(2): 193–205.(January 2003).doi:10.1016/s0092-8674(02)01284-9.PMID12553908.
“Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc”.Oncogene18(15): 2489–98.(April 1999).doi:10.1038/sj.onc.1202611.PMID10229200.
“Mlx, a new Max-like bHLHZip family member: the center stage of a novel transcription factors regulatory pathway?”.Oncogene19(29): 3266–77.(July 2000).doi:10.1038/sj.onc.1203634.PMID10918583.
“Cell cycle-dependent switch of up-and down-regulation of human hsp70 gene expression by interaction between c-Myc and CBF/NF-Y”.The Journal of Biological Chemistry274(34): 24270–9.(August 1999).doi:10.1074/jbc.274.34.24270.PMID10446203.
“p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression”.The Journal of Biological Chemistry277(35): 31694–702.(August 2002).doi:10.1074/jbc.M200266200.PMID12080043.
“MM-1, a novel c-Myc-associating protein that represses transcriptional activity of c-Myc”.The Journal of Biological Chemistry273(45): 29794–800.(November 1998).doi:10.1074/jbc.273.45.29794.PMID9792694.
“MM-1, a c-Myc-binding protein, is a candidate for a tumor suppressor in leukemia/lymphoma and tongue cancer”.The Journal of Biological Chemistry276(48): 45137–44.(November 2001).doi:10.1074/jbc.M106127200.PMID11567024.
“Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-beta-mediated induction of the CDK inhibitor p15(Ink4B)”.Molecular Cell9(1): 133–43.(January 2002).doi:10.1016/s1097-2765(01)00430-0.PMID11804592.
“Guanine nucleotide exchange factor, Tiam1, directly binds to c-Myc and interferes with c-Myc-mediated apoptosis in rat-1 fibroblasts”.The Journal of Biological Chemistry278(7): 5132–40.(February 2003).doi:10.1074/jbc.M206733200.PMID12446731.
“Repression of p15INK4b expression by Myc through association with Miz-1”.Nature Cell Biology3(4): 392–9.(April 2001).doi:10.1038/35070076.PMID11283613.
“Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability?”.Cell Cycle4(11): 1465–6.(November 2005).doi:10.4161/cc.4.11.2121.PMID16205115.
“Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant”.Genes & Development6(4): 642–54.(April 1992).doi:10.1101/gad.6.4.642.PMID1559612.
“DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation of c-Myc oncoprotein”.European Journal of Biochemistry / FEBS206(2): 595–603.(June 1992).doi:10.1111/j.1432-1033.1992.tb16964.x.PMID1597196.
“A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression”.The Journal of Biological Chemistry266(35): 23521–4.(December 1991).PMID1748630.
“Mapping of the MYC gene to band 8q24.12----q24.13 by R-banding and distal to fra(8)(q24.11), FRA8E, by fluorescence in situ hybridization”.Cytogenetics and Cell Genetics57(2–3): 109–11.(1991).doi:10.1159/000133124.PMID1914517.
“Nucleotide sequence 3' to the human c-myc oncogene; presence of a long inverted repeat”.Gene72(1–2): 105–8.(December 1988).doi:10.1016/0378-1119(88)90131-X.PMID3243428.
“A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas”.Cell52(2): 185–95.(January 1988).doi:10.1016/0092-8674(88)90507-7.PMID3277717.